Systemic administration is sufficient to target TTR in the liver and alleviate many of the devastating symptoms of TTR amyloidosis (ATTR), polyneuropathy [14, 15], and cardiomyopathy [16]. Here, TTR is linked to familial amyloid neuropathy.